Literature DB >> 8786059

Immunisation against hepatitis B in Taiwan.

I D Gust1.   

Abstract

Hepatitis B is hyperendemic in Taiwan; more than 15% of adults are chronic carriers of the virus and longterm sequelae (chronic active hepatitis, cirrhosis, and hepatocellular carcinoma) are common. A national immunisation programme was implemented in 1984 to tackle the problem. This entailed immunisation of newborn children, followed by susceptible school children and young adults. The programme, which has been in place for a decade, has resulted in a pronounced reduction in the prevalence of HBsAg among young children and seems to have led to a reduction in horizontal transmission among older children.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786059      PMCID: PMC1398048          DOI: 10.1136/gut.38.suppl_2.s67

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Vertical transmission of hepatitis B antigen in Taiwan.

Authors:  C E Stevens; R P Beasley; J Tsui; W C Lee
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

2.  Hepatitis B virus infection and chronic liver disease in Taiwan.

Authors:  D S Chen; J L Sung
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1978-12

3.  Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial.

Authors:  R P Beasley; L Y Hwang; C C Lin; C E Stevens; K Y Wang; T S Sun; F J Hsieh; W Szmuness
Journal:  Lancet       Date:  1981-08-22       Impact factor: 79.321

4.  A seroepidemiologic study of hepatitis B virus infection in Taiwan.

Authors:  D S Chen; J L Sung; M Y Lai
Journal:  Taiwan Yi Xue Hui Za Zhi       Date:  1978-12

5.  A mass hepatitis B vaccination programme in Taiwan: its preparation, results and reasons for uncompleted vaccinations.

Authors:  W C Wong; K K Tsang
Journal:  Vaccine       Date:  1994       Impact factor: 3.641

6.  A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers.

Authors:  D S Chen; N H Hsu; J L Sung; T C Hsu; S T Hsu; Y T Kuo; K J Lo; Y T Shih
Journal:  JAMA       Date:  1987-05-15       Impact factor: 56.272

7.  Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers.

Authors:  H M Hsu; D S Chen; C H Chuang; J C Lu; D M Jwo; C C Lee; H C Lu; S H Cheng; Y F Wang; C Y Wang
Journal:  JAMA       Date:  1988-10-21       Impact factor: 56.272

8.  Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program.

Authors:  Y J Tsen; M H Chang; H Y Hsu; C Y Lee; J L Sung; D S Chen
Journal:  J Med Virol       Date:  1991-06       Impact factor: 2.327

9.  Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan.

Authors:  H Y Hsu; M H Chang; D S Chen; C Y Lee; J L Sung
Journal:  J Med Virol       Date:  1986-04       Impact factor: 2.327

  9 in total
  7 in total

1.  Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B.

Authors:  S J Crowley; D Tognarini; P V Desmond; M Lees
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

2.  Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.

Authors:  Yu-Fen Tsai; Ching-I Yang; Jeng-Shiun Du; Ming-Hui Lin; Shih-Hao Tang; Hui-Ching Wang; Shih-Feng Cho; Yi-Chang Liu; Yu-Chieh Su; Chia-Yen Dai; Hui-Hua Hsiao
Journal:  PeerJ       Date:  2019-09-09       Impact factor: 2.984

3.  Impact of nucleic acid amplification test on pulmonary tuberculosis notifications and treatments in Taiwan: a 7-year single-center cohort study.

Authors:  Chih-Wei Wu; Yao-Kuang Wu; Chou-Chin Lan; Mei-Chen Yang; Ting-Qian Dong; I-Shiang Tzeng; Shu-Shien Hsiao
Journal:  BMC Infect Dis       Date:  2019-08-16       Impact factor: 3.090

4.  Association of HLA-DPA1, HLA-DPB1, and HLA-DQB1 Alleles With the Long-Term and Booster Immune Responses of Young Adults Vaccinated Against the Hepatitis B Virus as Neonates.

Authors:  Wen-Chang Wang; Yu-Shiang Lin; Yin-Fan Chang; Chih-Ching Yeh; Chien-Tien Su; Jin-Shang Wu; Fu-Hsiung Su
Journal:  Front Immunol       Date:  2021-08-18       Impact factor: 7.561

Review 5.  Insights into induction of the immune response by the hepatitis B vaccine.

Authors:  Federico Alejandro Di Lello; Alfredo Pedro Martínez; Diego Martín Flichman
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

6.  Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program.

Authors:  Yang-Cheng Hu; Chih-Ching Yeh; Ruey-Yu Chen; Chien-Tien Su; Wen-Chang Wang; Chyi-Huey Bai; Chi-Fei Chan; Fu Hsiung Su
Journal:  PeerJ       Date:  2018-02-16       Impact factor: 2.984

7.  Mortality trends in chronic liver disease and cirrhosis from 1981 to 2015 in Taiwan.

Authors:  Shih-Yung Su; Long-Teng Lee; Wen-Chung Lee
Journal:  Popul Health Metr       Date:  2021-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.